Partner Headlines - ALKS

  1. Non-Opioid Therapeutics And Significant Pain Treatments Make ...

    Benzinga
  2. Benzinga's Volume Movers

    Benzinga
  3. Morning Market Gainers

    Benzinga
  4. Underappreciated Leader Skips Over Equal-Weight In Double Upgrade

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga
  7. US Stock Futures Decline Ahead Of Housing Starts Report

    Benzinga
  8. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming ...

    Benzinga
  9. Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil ...

    Benzinga
  10. US Stock Futures Edge Lower; GDP Report In Focus

    Benzinga
  11. Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting ...

    Benzinga
  12. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  13. Benzinga's Top Initiations

    Benzinga
  14. Barclays Initiates Alkermes With Overweight

    Benzinga
  15. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  16. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD
  17. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  18. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  19. Alkermes pops to 15-year high

    IBD
  20. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  21. Morning Market Gainers

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Benzinga's Volume Movers

    Benzinga
  24. 3 Biotech ETFs Rally On Merger News

    Benzinga
  25. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  26. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  27. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  28. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  29. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  30. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  31. Alkermes' drug passes trial

    IBD
  32. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  33. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  34. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  35. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  36. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  37. Benzinga's Volume Movers

    Benzinga
  38. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  39. Morning Market Movers

    Benzinga
  40. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  41. Benzinga's Top Initiations

    Benzinga
  42. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  43. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  44. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  45. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  46. Stocks End Short Week With Big Losses

    IBD
  47. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  48. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  49. Ireland Home To Several Fast Growing Health Care Names

    IBD
  50. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  51. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  52. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  53. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  54. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  55. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  56. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  57. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  58. Alkermes

    IBD
  59. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  60. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  61. Alkermes

    IBD
  62. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  63. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  64. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  65. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  66. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  67. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  68. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  69. Stocks Pare Early Losses, End With Modest Declines

    IBD
  70. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  71. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  72. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  73. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  74. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  75. Dow Leads Market Higher As Volume Swells

    IBD
  76. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  77. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  78. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  79. Stocks Tumble On Disappointing Earnings Reports

    IBD
  80. Why Cisco, Google And Apple All Became Big Winners

    IBD
  81. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  82. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  83. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  84. Alkermes Writes New Prescription For Growth

    IBD
  85. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  86. Health Care Sector Wrap

    FoxBusiness
  87. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  88. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  89. Elan

    IBD
  90. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  91. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  92. Market Roundup

    Benzinga
  93. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  94. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  95. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  96. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  97. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  98. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  99. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  100. Benzinga's Top Pre-Market Gainers

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!